Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Page CP et al. | An in vivo model for studying platelet aggregation and disaggregation. | 1982 | Thromb. Haemost. | pmid:7051409 |
Bach MK | Mediators of anaphylaxis and inflammation. | 1982 | Annu. Rev. Microbiol. | pmid:6128957 |
Vargaftig BB | Platelet-activating factor (PAF-acether) | 1982 | Agents Actions | pmid:7164939 |
Bette P and Bienvenue A | Exchange of a spin-labeled analog of PAF-acether between micelles, serum albumin and model membranes. | 1982 | Agents Actions | pmid:7164940 |
Lartigue-Mattei C et al. | Pharmacokinetic study of PAF-acether. Preliminary results after the intravenous administration of a 3H-labelled product to the rabbit. | 1982 | Agents Actions | pmid:7164941 |
Morgat JL et al. | Radio-labelling of 1-O-alkyl, 2-O-acetyl, sn-glycero-3-phosphorylcholine, 1-O-(9,10-di3H)-octadecyl PAF-acether. | 1982 | Agents Actions | pmid:7164942 |
Convert O et al. | 1H NMR of PAF-acether: influence of solvent on its structure. | 1982 | Agents Actions | pmid:7164943 |
Borrel MC et al. | Additional techniques for the total synthesis of PAF-acether. | 1982 | Agents Actions | pmid:7164944 |
Benveniste J et al. | Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from three cell types. | 1982 | Agents Actions | pmid:7164945 |
Robeva R et al. | [Changes in blood coagulation in glomerulonephritis]. | 1982 | Vutr Boles | pmid:6219496 |
Chignard M et al. | Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. | 1982 | Eur. J. Pharmacol. | pmid:6804248 |
Shukla SD and Hanahan DJ | AGEPC (platelet activating factor) induced stimulation of rabbit platelets: effects on phosphatidylinositol, di- and triphosphoinositides and phosphatidic acid metabolism. | 1982 | Biochem. Biophys. Res. Commun. | pmid:6288030 |
Isobe J and Mizuno A | Aspects of PAF (platelet activating factor)-induced aggregation by using rabbit platelets. | 1982 | Tokushima J. Exp. Med. | pmid:7170716 |
Czarneztki BM | Effect of platelet activating factor on leukocytes. II. Enhancement of eosinophil chemotactic factor and beta-glucuronidase release. | 1982 | Chem. Phys. Lipids | pmid:6814773 |
Jouvin-Marche E et al. | Platelet-activating factor (PAF-acether), an activator of neutrophil functions. | 1982 | Agents Actions | pmid:6299078 |
Caillard CG et al. | Hypotensive activity of PAF-acether in rats. | 1982 | Agents Actions | pmid:6299079 |
Camussi G et al. | Release of platelet-activating factor from HL-60 human leukemic cells following macrophage-like differentiation. | 1982 | Blood | pmid:6947829 |
Ishii H et al. | A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. | 1982 | Thromb. Res. | pmid:6897588 |
Wasserman SI | Mediators of immediate hypersensitivity. | 1983 | J. Allergy Clin. Immunol. | pmid:6193157 |
Hopkins NK et al. | Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. | 1983 | Biochim. Biophys. Acta | pmid:6313071 |
Mencia-Huerta JM et al. | Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE. | 1983 | J. Immunol. | pmid:6315819 |
Czarnetzki B | Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. | 1983 | Clin. Exp. Immunol. | pmid:6317241 |
Stimler NP and O'Flaherty JT | Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. | 1983 | Am. J. Pathol. | pmid:6624879 |
Hartung HP | Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. | 1983 | FEBS Lett. | pmid:6309563 |
Shukla SD et al. | Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. | 1983 | J. Biol. Chem. | pmid:6309795 |
Heffner JE et al. | Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. | 1983 | J. Clin. Invest. | pmid:6822668 |
Keraly CL et al. | Effect of structural analogues of PAF-acether on platelet desensitization. | 1983 | Br. J. Haematol. | pmid:6824590 |
Tence M et al. | The enantiomer and the positional isomer of platelet-activating factor. | 1983 | Biochim. Biophys. Acta | pmid:6824744 |
Camussi G et al. | Biosynthesis and release of platelet-activating factor from human monocytes. | 1983 | Int. Arch. Allergy Appl. Immunol. | pmid:6826235 |
Randolph AE et al. | Blood pressure and heart rate effects of alkyl ether phospholipids in conscious renal, spontaneously hypertensive, and normotensive rats. | 1983 | Clin Exp Hypertens A | pmid:6684006 |
Morley J et al. | Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. | 1983 | Br. J. Pharmacol. | pmid:6685552 |
Hornby EJ and Perry CR | 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. | 1983 | Thromb. Haemost. | pmid:6636035 |
Patterson R and Harris KE | The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. | 1983 | J. Lab. Clin. Med. | pmid:6644157 |
Nunn B | Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. | 1983 | Thromb. Res. | pmid:6648898 |
Myers A et al. | Glucocorticoid protection against PAF-acether toxicity in mice. | 1983 | Br. J. Pharmacol. | pmid:6652344 |
Ogihara T et al. | [Renomedullary hypotensive lipids and prostaglandins]. | 1983 | Horumon To Rinsho | pmid:6368051 |
Worthen GS et al. | Platelet-activating factor causes neutrophil accumulation and edema in rabbit lungs. | 1983 | Chest | pmid:6839840 |
Heffner JE et al. | Platelet-induced pulmonary hypertension and edema. A mechanism involving acetyl glyceryl ether phosphorylcholine and thromboxane A2. | 1983 | Chest | pmid:6839854 |
Levy JV | Calmodulin antagonist W-7 inhibits aggregation of human platelets induced by platelet activating factor. | 1983 | Proc. Soc. Exp. Biol. Med. | pmid:6844347 |
O'Flaherty JT et al. | Platelet-activating factor and analogues: comparative studies with human neutrophils and rabbit platelets. | 1983 | Res. Commun. Chem. Pathol. Pharmacol. | pmid:6844746 |
Valone FH and Goetzl EJ | Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. | 1983 | Immunology | pmid:6848449 |
Chilton FH et al. | Metabolic fate of platelet-activating factor in neutrophils. | 1983 | J. Biol. Chem. | pmid:6853486 |
Stormorken H et al. | A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). | 1983 | Thromb. Res. | pmid:6857589 |
Kloprogge E et al. | Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. | 1983 | Thromb. Res. | pmid:6857605 |
Lecrubier C et al. | Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. | 1983 | Agents Actions | pmid:6858789 |
Virella G et al. | Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. | 1983 | Immunology | pmid:6885111 |
Camussi G et al. | Platelet-activating factor-mediated contraction of rabbit lung strips: pharmacologic modulation. | 1983 | Immunopharmacology | pmid:6885382 |
Hubbard JW et al. | Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats. | 1983 | Life Sci. | pmid:6337313 |
Acharya SB and MacIntyre DE | Platelet products and vascular PGI2 production. | 1983 | Prostaglandins Leukot Med | pmid:6338532 |
Camussi G et al. | Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. | 1983 | Immunology | pmid:6339375 |